Investigation of Copper-64-Based Host–Guest Chemistry Pretargeted Positron Emission Tomography
- 14 June 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (7) , 2268-2278
Abstract
Pretargeting is a technique that uses macromolecules as targeting agents for nuclear imaging and therapy with the goal of reducing the radiation toxicity to healthy tissues often associated with directly radiolabeled macromolecules. In pretargeting, a macromolecule is radiolabeled in vivo at the target site using a radiolabeled small molecule (radioligand) that interacts with the macromolecule with high specificity. We report an investigation of host-guest chemistry-driven pretargeting using copper-64 radiolabeled ferrocene (Fc; guest) compounds and a cucurbit[7]uril (CB7; host) molecule functionalized carcinoembryonic antigen targeting hT84.66-M5A monoclonal antibody (CB7-M5A). Two novel ferrocene-based radioligands ([64Cu]Cu-NOTA-PEG3-Fc and [64Cu]Cu-NOTA-PEG7-Fc) were prepared, and their in vitro stability, pharmacokinetic in vivo profile in healthy mice, and pretargeting performance in a subcutaneous BxPC3 human pancreatic cancer cell xenograft mouse model were compared. The antibody dosing was optimized using a zirconium-89 radiolabeled M5A antibody ([89Zr]Zr-DFO-M5A) in a BxPC3 xenograft model, and the dosimetry of [89Zr]Zr-DFO-M5A and the pretargeting approach were compared. Finally, the effects of varying lag times up to 9 days between CB7-M5A and radioligand injection were investigated. In vivo pretargeting studies with both ferrocene radioligands resulted in specific tumor uptake (p = 0.0006 and p = 0.003) and also showed that the host-guest-based pretargeting approach excels with extended lag times up to 9 days with good tumor localization, suggesting that host-guest pretargeting may be suitable for use without clearing agents which have complicated clinical application of this technique. To our knowledge, the reported lag time of 9 days is the longest investigated lag time in any reported pretargeting studies.Keywords
Funding Information
- Foundation for the National Institutes of Health (1S10 RR023680-1)
- National Institute of Biomedical Imaging and Bioengineering (1R21EB027982)
This publication has 33 references indexed in Scilit:
- Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Diels–Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled AntibodyJournal of Nuclear Medicine, 2013
- Highly Reactive trans-Cyclooctene Tags with Improved Stability for Diels–Alder Chemistry in Living SystemsBioconjugate Chemistry, 2013
- Synthesis, Cu(ii) complexation,64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant armsDalton Transactions, 2011
- Cucurbituril chemistry: a tale of supramolecular successRSC Advances, 2011
- Molecular Recognition of Insulin by a Synthetic ReceptorJournal of the American Chemical Society, 2011
- Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo studyOrganic & Biomolecular Chemistry, 2010
- Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stabilityCancer Immunology, Immunotherapy, 2008
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaBlood, 2004
- Humanization of the anti-CEA T84.66 antibody based on crystal structure dataProtein Engineering, Design and Selection, 2004